Navigation Links
Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries
Date:10/6/2010

eding that may result from the Arbitration Demand. Forward Looking Statements
Statements contained in this press release that are not based on historical fact, including without limitation
statements containing the words "believes," "may," "plans," "will," "estimates," "continues," "anticipates,"
"intends," "expects" and similar expressions, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and constitute "forward-looking information" within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the "safe harbor" provisions of applicable securities legislation. Forward-looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for the remainder of 2010 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research and development and product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements.  Many such known risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions in the United States, Canada and the other regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental legislation and regulations and changes in, or the failure to comply with, governmental legislation and regulations; availability of financial reimbursement coverage from governmental
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010
2. Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients
3. Angiotech Pharmaceuticals Announces Conference Call and Webcast
4. Angiotech announces exclusive distribution agreement with B. Braun for Angiotechs proprietary Quill(TM) SRS product line
5. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
6. Angiotech Pharmaceuticals Announces Conference Call and Webcast
7. Angiotech Pharmaceuticals, Inc. Announces Conference Call and Webcast
8. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
9. Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
10. Angiotechs Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent
11. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Dr. Greg Leyer of UAS Labs recently was ... Pre-Conference seminar on probiotics in San Diego, CA. , ... conference for health care professionals. This year’s pre-conference seminar was ... in health. Dr. Leyer spoke about the emerging topics and ...
(Date:1/22/2015)... SAN DIEGO , Jan. 22, 2015   ... company, and Sequenom, Inc. (NASDAQ: SQNM ... a development agreement for next generation noninvasive prenatal ... Cypher,s genome interpretation technology, called Mantis™, to advance ...
(Date:12/24/2014)... Dec. 24, 2014  United Therapeutics Corporation (NASDAQ: ... MDT ) has submitted a pre-market approval application ... the use of Medtronic,s SynchroMed ® II implantable ... use with United Therapeutics, Remodulin ® (treprostinil) Injection ...
(Date:12/24/2014)... Louis, Missouri (PRWEB) December 23, 2014 GMO ... biotechnology company, Syngenta, are in the process of being consolidated ... case is In Re: Syngenta AG MIR 162 Corn Litigation, ... District of Kansas. , Management of the Syngenta GMO corn ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... Early ... 2008 -, ... products company, announced today that it,has received a "positive opinion" recommending European ... chronic,renal failure and chemotherapy-induced anemia. Retacrit is a similar,biologic -- often referred ...
... WALNUT CREEK, CA It is better to be looked over ... of wisdom for genome data-miners of today. Data that ... to the discerning eye. Such is the case of a ... Institute (DOE JGI) of the massive backlog of microbial genome ...
... delicious when cooked in a white wine broth, but ... put in a pot: they stick to virtually all ... tenacity. , Northwestern University biomedical engineer Phillip B. Messersmith ... of the bonds; now he has produced a versatile ...
Cached Biology Technology:Hospira's Biosimilar Epoetin Retacrit(TM) Receives Positive Opinion Recommending EU Approval 2Hospira's Biosimilar Epoetin Retacrit(TM) Receives Positive Opinion Recommending EU Approval 3Massive reanalysis of genome data solves case of the lethal genes 2Sticky mussels inspire biomedical engineer yet again 2Sticky mussels inspire biomedical engineer yet again 3
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... of the "The Global Watermarking and Fingerprinting ... http://photos.prnewswire.com/prnh/20130307/600769 This ... media watermarking and fingerprinting markets. Watermarking aims to ...
(Date:12/19/2014)... Dec. 18, 2014   LaunchKey , the first decentralized ... and Internet of Things era, today announced the close ... round was led by Metamorphic Ventures with participation from ... VegasTechFund, and others.  LaunchKey has raised $4 million to ...
(Date:12/17/2014)... Dec. 16, 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report to their ... One major trend upcoming in this market is ... Chemical sensors help in recording of patient data for ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... in the September 2007 issue of the Journal ... ARTICLE HIGHLIGHTS Renal transplant recipients genetic ... chemicals New anti-inflammatory compound discovered Thematic Review: Understanding how ... Renal transplant recipients genetic makeup does not negatively impact ...
... Pennsylvania researchers have designed a nanoscale system to ... external forces. By combining microfabricated cantilevers ... sensors, the study showed that cells respond to ... between cells and their environment. The study also ...
... new light on the health effects of exposure to dust ... Center disaster on September 11, 2001. The data, drawn from ... the 25,000 rescue and recovery workers enrolled in the Registry ... is 12 times what would be normally expected for the ...
Cached Biology News:Story ideas from the Journal of Lipid Research 2Story ideas from the Journal of Lipid Research 3Story ideas from the Journal of Lipid Research 4Story ideas from the Journal of Lipid Research 5Bioengineers at University of Pennsylvania devise nanoscale system to measure cellular forces 2Survey finds elevated rates of new asthma among WTC rescue and recovery workers 2Survey finds elevated rates of new asthma among WTC rescue and recovery workers 3
... multicolor analysis in a modern flow cytometer, ... that are differentially labeled with fluorescent probes. ... typically used for cell labeling are broader ... a flow cytometers filters. Thus, the fluorescence ...
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: rack ...
... ActiveSight, the leading provider of ... design, offers fragment-based screening services to ... screening involves the binding of drug-like ... crystallized protein drug targets, allowing scientists ...
...
Biology Products: